Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Lilly’s Galcanezumab Clears PAFSC Review, 1st Antibody for Migraine Prevention
December 3, 2020
- Finance Minister Pushed for All-Product Re-Pricing in 2021: CEFP Minutes
December 3, 2020
- Chuikyo Reps Raise No Opposition to Off-Year Re-Pricing, Still Split over Product Scope
December 3, 2020
- MHLW to Issue Notification to Urge Drug Makers’ Prompt Info Provisioning on Supply Shortages
December 3, 2020
- Japan Diet Clears Immunization Bill
December 2, 2020
- Japan’s Volume-Based Generic Share 78.3% in September, Fails to Hit Govt Goal
December 2, 2020
- Average NHI-Market Price Gap at 8.0%: MHLW
December 2, 2020
- Japan’s Healthcare Spend Rises to 43.4 Trillion Yen in FY2018
December 2, 2020
- MHLW Approves Label Expansions for Forxiga, Trelegy, Evrenzo, Cabometyx and More
November 30, 2020
- Ono’s Cancer Cachexia Drug to Finally Come Up for PAFSC Review on Dec. 11
November 30, 2020
- MHLW Says 7,500 Vaccine Freezers for Storage at Minus 20 Degrees C, Presumably for Moderna Shot
November 30, 2020
- CEFP Member Urges Off-Year Re-Pricing for Preferably All Products, At Least 80%
November 30, 2020
- Japan to Set New Generic Target by March-End: Health Minister
November 30, 2020
- ICH to Stick to Urgent Topics with Significant Impact for Now amid COVID-19
November 30, 2020
- Orphan Drug Status Granted for Lilly’s Selpercatinib, 6 More APIs
November 27, 2020
- Japan Diet Expected to Enact Immunization Bill on Dec. 2
November 27, 2020
- COVID-19 Vaccines Not Actively Recommended for Children: Professor
November 27, 2020
- Second CAR-T Therapy Yescarta Up for Panel Review; MHLW to Report Corrective Measures for Zolgensma Issue
November 27, 2020
- LDP Health Policy Clique Set to Urge Govt to Skip Off-Year Re-Pricing Next Year, but Explore Middle Ground at Same Time
November 27, 2020
- PM Says to Get COVID-19 Shot When His Turn Comes Around
November 26, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…